In 2019, around 71 percent of the total oncology drug market in the United States were generated by the 20 top-selling cancer medicines. The share of 20 top-selling medicines in the United Kingdom was around 58 percent of the total oncology market.

The statistic shows the total non-oncology precision medicine market size worldwide in 2019 and a forecast for 2030. In 2019, the global precision medicine market excluding oncology generated some 41 billion U.S. dollars. By 2030, it is estimated that this market will increase up to 130 billion dollars.

The global radiation oncology market size reached USD 8.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.3% during 2025-2033. Technological advancements, rising cancer incidence, increasing awareness regarding oncology radiation, government initiatives, and collaborations, regulatory approvals for new therapies, and the trend towards personalized medicine are some of the factors fostering the market growth.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 8.6 Billion
Market Forecast in 2033	USD 14.9 Billion
Market Growth Rate 2025-2033	6.3%

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on the type, technology, application, and end user.

In 2022, the global market for cancer drugs was estimated at 147 billion U.S. dollars. By 2032, this market is forecasted to reach over 300 billion U.S. dollars. This statistic illustrates the size of the cancer drug market worldwide in 2022 and 2032.

Oncology informatics market segmented global market by type (Role of EHR in Oncology, Features of Oncology EHR, Installation of Oncology EHR), by region & end user.

The immuno-oncology assay market is estimated to be valued at US$ 5.6 billion in 2024. The immuno-oncology assay market is predicted to rise at a CAGR of 12.4% from 2024 to 2034. The global immuno-oncology assay market is anticipated to reach US$ 18.1 billion by 2034.

Attributes	Key Insights
Estimated Market Size in 2024	US$ 5.6 billion
Projected Market Value in 2034	US$ 18.1 billion
Value-based CAGR from 2024 to 2034	12.4%

2019 to 2023 Historical Analysis vs. 2024 to 2034 Market Forecast Projections

Historical CAGR from 2019 to 2023	15.4%
Forecast CAGR from 2024 to 2034	12.4%

Country-wise Analysis

Countries	Forecast CAGRs from 2024 to 2034
The United States	12.1%
The United Kingdom	13.9%
China	13.3%
Japan	14.1%
South Korea	15.2%

Category-wise Insights

Category	CAGR from 2024 to 2034
Reagents and Antibodies	12.2%
Checkpoint Inhibitors	11.9%

Report Scope

Attributes	Details
Estimated Market Size in 2024	US$ 5.6 billion
Projected Market Valuation in 2034	US$ 18.1 billion
Value-based CAGR 2024 to 2034	12.4 %
Forecast Period	2024 to 2034
Historical Data Available for	2019 to 2023
Market Analysis	Value in US$ billion
Key Regions Covered	North America Latin America Western Europe Eastern Europe South Asia and Pacific East Asia Middle East and Africa
Key Market Segments Covered	Product Technology Indication End-user Application Region
Key Countries Profiled	The United States Canada Brazil Mexico Germany The United Kingdom France Spain Italy Russia Poland Czech Republic Romania India Bangladesh Australia New Zealand China Japan South Korea GCC countries South Africa Israel
Key Companies Profiled	AGILENT TECHNOLOGIES Sartorius AG NanoString Technologies THERMO FISHER SCIENTIFIC BIO-RAD LABORATORIES F. HOFFMANN-LA ROCHE LTD. PERKINELMER ILLUMINA QIAGEN N.V. Charles River Laboratories

India cancer diagnostics market size reached USD 7.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.2 Billion by 2033, exhibiting a growth rate (CAGR) of 7.13% during 2025-2033. The ongoing advancements in diagnostic technologies, such as molecular diagnostics, next-generation sequencing, and liquid biopsy, which have improved the accuracy and efficiency of cancer diagnostics, are driving the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 7.3 Billion
Market Forecast in 2033	USD 14.2 Billion
Market Growth Rate (2025-2033)	7.13%

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on product, technology, application, and end user.

The global oncology immuno drug market is experiencing robust growth, driven by the increasing prevalence of cancer and the development of innovative immunotherapies. The market size was valued at XXX million in 2019 and is projected to reach XXX million by 2023, exhibiting a CAGR of XX% during the forecast period. Key factors propelling market growth include the rising adoption of personalized medicine approaches in cancer treatment, the increasing awareness of immunotherapy, and the development of combination therapies. Nevertheless, the high cost of oncology immuno drugs and the potential for severe side effects pose certain restraints on market growth. The market is segmented by application (solid tumors, hematologic malignancies) and type (monoclonal antibodies, checkpoint inhibitors, adoptive cell therapies). The presence of established players such as Bristol-Myers Squibb, Merck & Co, and Roche AG, along with the emergence of numerous small and medium-sized companies, characterizes the competitive landscape. Strategic initiatives such as mergers, acquisitions, and collaborations are being undertaken to strengthen the product portfolios and expand market share.

The global oncology molecular diagnostics market size reached USD 4.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.3 Billion by 2033, exhibiting a growth rate (CAGR) of 12.37% during 2025-2033. The rising prevalence of cancer, ongoing advancements in molecular diagnostic technologies, and increased adoption of precision medicine are primarily driving the market's growth.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 4.8 Billion
Market Forecast in 2033	USD 14.3 Billion
Market Growth Rate 2025-2033	12.37%

IMARC Group provides an analysis of the key trends in each segment of the global oncology molecular diagnostics market report, along with forecasts at the global, regional, and country levels from 2025-2033. Our report has categorized the market based on cancer type, product, technology, and end-user.

India cancer immunotherapy market size reached USD 4.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.9 Billion by 2033, exhibiting a growth rate (CAGR) of 9.60% during 2025-2033. The increasing shift towards personalized medicine, which has increased interest in immunotherapies, as they offer the potential for more targeted and less toxic treatments, is driving the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 4.0 Billion
Market Forecast in 2033	USD 9.9 Billion
Market Growth Rate (2025-2033)	9.60%

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for ​2025-2033​. Our report has categorized the market based on therapy type, application, and end user.

Snapshot img

Cancer Biologics Market Size 2025-2029

The cancer biologics market size is forecast to increase by USD 84.5 billion at a CAGR of 10.7% between 2024 and 2029.

The market is experiencing significant growth driven by the rising global incidence of cancer, which is projected to reach over 20 million new cases annually by 2030. This trend presents a substantial opportunity for market participants, particularly in developing countries where the unmet medical need is high. However, the market is challenged by the high cost of cancer biologics, which limits access for many patients, especially in low- and middle-income countries. This dynamic underscores the need for innovative pricing strategies and potential collaborations between stakeholders to expand patient access.
As the market evolves, companies must stay abreast of emerging trends, including the increasing use of personalized medicine, the growing importance of immuno-oncology therapies, and the development of cancer vaccines. Additionally, artificial intelligence is playing a key role in accelerating drug discovery, optimizing treatment plans, and improving patient outcomes through data-driven insights. By capitalizing on these opportunities and navigating challenges effectively, market players can position themselves for long-term success in the oncology market.

What will be the Size of the Cancer Biologics Market during the forecast period?

Request Free Sample

The market encompasses a diverse range of innovative treatments derived from living organisms, including monoclonal antibodies, gene therapies, and cell-based immunotherapies. These advanced therapies target specific molecular markers in cancer biology, moving beyond traditional chemotherapy's broad-spectrum approach. Reimbursement policies, in collaboration with insurance providers, are evolving to accommodate the unique requirements and costs associated with biologic drugs. Hospital pharmacies, retail pharmacies, and online pharmacies are key distribution channels for these complex treatments.
Colorectal cancer and other indications continue to drive market growth, with ongoing research and development efforts expanding the therapeutic landscape. The market's dynamic nature reflects the relentless pursuit of effective, personalized cancer treatments.

How is this Cancer Biologics Industry segmented?

The cancer biologics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Monoclonal antibodies
  Cell and gene therapy
  Vaccines
  Others


Route Of Administration

  Injectable
  Oral


Type

  Breast cancer
  Lung cancer
  Colorectal cancer
  Prostate cancer
  Others


Distribution Channel

  Hospitals
  Clinics
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  Asia
  Rest of World (ROW)

By Product Insights

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period.

Monoclonal antibodies are essential therapeutic products in cancer treatment, particularly in targeted therapies and cancer immunotherapy. These biological drugs work by binding to specific molecular targets on cancer cells, inhibiting tumor growth signals and altering cancer cell behavior. Monoclonal antibodies have minimal side effects as they primarily affect cancer cells, making them a popular choice among medical oncologists, radiation oncologists, and specialized nurses. The monoclonal antibodies segment dominates the oncology biologics market, with HER2-targeted antibodies, EGFR inhibitors, and immune checkpoint inhibitors being notable examples. In the field of cell-based immunotherapies, CAR-T cell therapies employ monoclonal antibodies to target cancer cells, inducing an immune response against them.

The aging population and lifestyle changes contribute to the increasing cancer incidence, driving the demand for innovative treatments. In August 2023, the FDA approved Johnson & Johnson's Talvey (talquetamab-tgvs), a bispecific antibody targeting CD3 and GPRC5D, for relapsed or refractory multiple myeloma. This approval underscores the importance of continued research and advancements in cancer biology and biotechnology. The regulatory environment, healthcare expenditure, and insurance providers play a crucial role in the market's growth. The market also includes various diagnostic techniques, academic institutions, and research organizations. Biologic therapies, including monoclonal antibodies and cell-based immunotherapies, are administered through various routes, such as oral or injection, and are available at hospitals, medical oncology centers, and through hospital and retail pharmacies.

Despite their benefits, monoclonal anti

Immuno-Oncology Assays Market size is growing with a CAGR of 11.4% in the prediction period and it crosses USD 11.82 Bn by 2032 from USD 5.55 Bn in 2025.

The global cancer diagnostics market size reached USD 207.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 326.2 Billion by 2033, exhibiting a growth rate (CAGR) of 4.88% during 2025-2033. The growing awareness about early detection of disease, rising prevalence of cancer due to lifestyle changes and genetic predisposition, and advancements in diagnostics techniques to enhance patient care are some of the major factors propelling the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 207.9 Billion
Market Forecast in 2033	USD 326.2 Billion
Market Growth Rate (2025-2033)	4.88%

IMARC Group provides an analysis of the key trends in each segment of the global cancer diagnostics market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on product, technology, application and end user.

The global ovarian cancer market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.59% during 2025-2033. The rising incidence of ovarian cancer cases, the emergence of personalized medicine in cancer care, and the implementation of government Initiatives to raise awareness, promote early detection, and support research represent some of the key factors driving the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 2.3 Billion
Market Forecast in 2033	USD 5.5 Billion
Market Growth Rate (2025-2033)	9.59%

IMARC Group provides an analysis of the key trends in each segment of the global ovarian cancer market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on type, treatment type and end user.

The global neuroendocrine tumors (NETs) therapeutics market is experiencing robust growth, driven by increasing prevalence of NETs, advancements in diagnostic technologies leading to earlier detection, and the emergence of novel targeted therapies. The market's expansion is further fueled by rising healthcare expenditure, growing awareness among patients and healthcare professionals about NETs, and supportive regulatory frameworks facilitating drug approvals. While the exact market size for 2025 is not provided, considering a plausible CAGR of 8% (a reasonable estimate given the growth drivers) and a base year value of (let's assume) $5 billion in 2019, the market size in 2025 could be estimated around $7-8 billion. This assumes a relatively consistent growth rate, acknowledging that market fluctuations can occur. Major pharmaceutical companies such as F. Hoffmann-La Roche Ltd, Ipsen Pharma, Merck & Co., Inc, Novartis AG, and Pfizer Inc. are actively involved in research and development, contributing significantly to the market's growth with their innovative treatment options. Segmentation by type (e.g., pancreatic NETs, gastroenteropancreatic NETs) and application (e.g., chemotherapy, targeted therapy, hormone therapy) helps to pinpoint high-growth segments, allowing for focused market analysis and strategic decision-making. Regional variations will exist, with North America and Europe currently dominating due to higher healthcare expenditure and advanced healthcare infrastructure, though the Asia-Pacific region is expected to witness significant growth in the forecast period due to rising healthcare awareness and improving healthcare access. The market faces constraints such as the relative rarity of certain NET subtypes, high treatment costs, and potential side effects associated with some therapies. Nevertheless, ongoing research and development efforts are expected to address these challenges and further propel market growth in the coming years. The forecast period (2025-2033) promises continued expansion driven by innovative treatment approaches and an improved understanding of NETs. Factors such as personalized medicine, advancements in imaging technologies, and increased clinical trial activity are likely to contribute significantly to the growth trajectory. A deeper understanding of the tumor's biology is enabling the development of more targeted and effective therapies. Further expansion of access to advanced therapies, particularly in emerging markets, will be a major driver for market expansion. Continued investment in research and development is critical to addressing unmet medical needs and improving patient outcomes within this segment. Competitive landscape analysis across major players and emerging entrants will be vital for success in this dynamically evolving sector.

Overview

New York, NY – March 21, 2025 – The Global Hormone Refractory Prostate Cancer Market size is expected to be worth around USD 20.1 Billion by 2033 from USD 7.9 Billion in 2023, growing at a CAGR of 9.8% during the forecast period from 2024 to 2033.

Hormone-refractory prostate cancer (HRPC), also known as castration-resistant prostate cancer (CRPC), is an advanced form of prostate cancer that continues to progress despite androgen deprivation therapy (ADT). As prostate cancer cells adapt to low testosterone levels, they become resistant to conventional hormone treatments, making HRPC more challenging to manage.

The rising incidence of HRPC has driven significant advancements in targeted therapies, immunotherapies, and chemotherapy options. Novel agents such as androgen receptor inhibitors, next-generation hormone therapies, and radiopharmaceuticals have improved survival rates and patient outcomes. The U.S. Food and Drug Administration (FDA) has approved several innovative drugs, including enzalutamide, abiraterone acetate, and radium-223, offering new hope for patients.

North America dominates the HRPC treatment market due to high diagnosis rates and advanced healthcare infrastructure. However, the Asia-Pacific region is expected to witness substantial growth driven by increasing prostate cancer cases and improving healthcare access.

Key industry players driving innovation in HRPC treatment include Pfizer Inc., Johnson & Johnson, Bayer AG, Astellas Pharma Inc., and Bristol-Myers Squibb. Ongoing research and clinical trials continue to explore novel combination therapies, offering promising prospects for the future of HRPC management.

https://sp-ao.shortpixel.ai/client/to_auto,q_lossy,ret_img,w_1216,h_735/https://market.us/wp-content/uploads/2019/07/Hormone-Refractory-Prostate-Cancer-Market-Size.jpg" alt="Hormone Refractory Prostate Cancer Market Size" class="wp-image-115914">

The global pet cancer therapeutics market size reached USD 320.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 664.8 Million by 2033, exhibiting a growth rate (CAGR) of 8.03% during 2025-2033. The increasing pet ownership rates and human-animal bond, advancements in veterinary medicine and research, and growing awareness about the availability and benefits of pet cancer therapeutics are some of the major factors propelling the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 320.2 Million
Market Forecast in 2033	USD 664.8 Million
Market Growth Rate (​​​​​​​2025-2033)	8.03%

IMARC Group provides an analysis of the key trends in each segment of the global pet cancer therapeutics market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on therapy, animal species, cancer type and end user.

The statistic shows the distribution of the global non-oncology precision medicine market in 2019, by region. In that year, the global precision medicine market generated some 41 billion U.S. dollars of which some 41 percent was generated by North America.

The cancer biomarker market size is projected to grow from $ 28.6 billion in 2024 to $ 46.7 billion by 2035, representing a CAGR of 5% during the forecast period from 2024 to 2035

global peptide based cancer therapeutics market was valued at USD 8.58 billion in 2019 and is expected to reach USD 17.18 billion by 2027, growing at a CAGR of 9.1% from 2020-2027